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Background
Familial Mediterranean Fever (FMF) is an autosomal
recessive disease which is characterized by recurrent, self-
limiting, short attacks of serositis (peritonitis, pleuritis or
arthritis), fever and erysipelas-like skin lesions along with a
marked increase in acute phase reactants. Although FMF
is not associated with immune-mediated tissue damage,
however these individuals are prone to develop type AA
amyloidosis and associated renal impairment progressing
eventually to renal failure as the most severe long term
complications. Colchicine is the best treatment option for
the time being, however 10 to 15% of patient with FMF
are unresponsive or intolerant to colchicine. for those
cases recent literature review have shown successful use of
biologic agents in management.
The case
We present a challenging case of FMF in a 14 yrs old syr-
ian girl who was diagnosed to have FMF at age of 6 years,
she was started on colchicine at the age of 8 years, family
history was significant for FMF and two of the family
members developed renal amyloidosis requiering renal
transplant. She presented to the clinic at 12 yrs old with
bilateral ankle swelling. On examination she was found
to have bilateral lower limb edema, her lab tests were sig-
nificant for albumin of 18, urinalysis was positive for +4
proteins, renal biopsy was done which confirmed renal
amyloidosis. The girl was on colchicine, we maximised
the dose but the proteinuria persisted, she was also
started on multiple courses of steroids and methotrexate
with short lived improvement only. After reviewing the
literature we found case reports that describe the suc-
cessful use of biological agents especially anakinra (inter-
leukin 1 receptor antagonist) in treatment of resistant
cases of FMF with success. It was decided then to place
her on anakinra, 2 months after being on anakinra we
witnessed a significant improvement the edema totally
resolved and amyloid protein has decreased from 203 to
less than 5 (normal value).
Discussion
The major cause of mortality in FMF is the insidious
development of secondary (AA) amyloidosis with even-
tual renal failure. Treatment of FMF is centered on pre-
vention of painful attacks and the development of
amyloidosis. Colchicine has been the main stay for treat-
ment of FMF since 1974. Since then colchicine has been
used to prevent and treat the acute attacks of FMF but
in 10-15 % of pt, the response to colchicine may be
minimal or absent. These patients also have an
increased risk of developing amyloidosis. For such cases
some of the newly discovered biological agent like: ana-
kinra (IL-1 receptor antagonist) and etanercept have
been tried with promising results, however the the clini-
cal efficacy and safety of these agents are yet to be
determined
Conclusion
The new discovery of biological agents has changes the
outcome of many rheumatological diseases especially in
paediatric population. A few colchicine resistant FMF
patients have shown responsiveness to anakinra (an
interleukin-1 receptor antagonist). However, the true
efficacy and safety of treatment with biological agents
remains uncertain because of the paucity of reports and
absence of controlled trials.
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